| Identification | Back Directory | [Name]
UKI-1 | [CAS]
220355-63-5 | [Synonyms]
UKI-1
UKI-1C
1-Piperazinecarboxylic acid, 4-[(2S)-3-[3-(aminoiminomethyl)phenyl]-1-oxo-2-[[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino]propyl]-, ethyl ester | [Molecular Formula]
C32H47N5O5S | [MOL File]
220355-63-5.mol | [Molecular Weight]
613.81 |
| Chemical Properties | Back Directory | [Boiling point ]
745.5±70.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 28 mg/mL (45.62 mM) | [form ]
Solid | [pka]
9.76±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells[1][2]. | [in vivo]
UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models[1]. | [storage]
Store at -20°C | [References]
[1] Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. DOI:10.1002/ijc.20192
[2] Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301(2):465-75. DOI:10.1006/jmbi.2000.3966 |
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|